Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Clinical trial NCT06333899 · RECRUITING

Trial details

NCT number: NCT06333899
Sponsor: Nationwide Children's Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

High Grade Glioma Diffuse Intrinsic Pontine Glioma Anaplastic Astrocytoma Infant Type Hemispheric Glioma Glioblastoma Glioblastoma Multiforme WHO Grade III Glioma WHO Grade IV Glioma Diffuse Midline Glioma, H3K27-altered

Start date: 2025-08-03
Primary completion: 2029-07-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.